Recent Updates — NRSN
NeuroSense Therapeutics signed a strategic collaboration with an advisor to advance the revenue-generating supply of its lead ALS candidate, PrimeC, through a licensed clinical treatment center in the U.S. The company targets generating first revenues from PrimeC supply in the first half of 2027, contingent on completing legal, regulatory, and operational requirements. Consideration for the advisor includes equity and a success-based percentage of net revenues from qualifying sales. This agreement aims to establish an initial revenue stream while the company continues clinical programs for ALS and Alzheimer's disease. NeuroSense Therapeutics is a biotechnology company developing therapeutic candidates for neurodegenerative diseases.
NeuroSense Therapeutics filed a U.S. patent application covering methods of treating traumatic brain injury (TBI) and related central nervous system injuries using its lead drug candidate, PrimeC. The application covers concussion, blast-related injury, and chronic traumatic encephalopathy (CTE), with potential protection through 2047 if granted. This filing supports the company's strategy to expand PrimeC beyond its primary ALS development program into a broader neurological market lacking approved disease-modifying therapies. NeuroSense Therapeutics is a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases.
The Nasdaq Hearings Panel has scheduled a hearing for November 10, 2026, regarding NeuroSense Therapeutics' appeal of the October 1 staff determination to delist its securities. The company regained compliance with the $1.00 minimum bid price requirement but remains deficient in meeting the $35 million minimum market value of listed securities standard. Management intends to present a plan to satisfy listing requirements or an alternative equity standard during the hearing, requesting an exception period of up to 180 days. Shares continue trading pending the Panel's decision. The company also highlighted upcoming milestones, including a New Drug Submission for PrimeC in ALS targeted for December 2026 and a funding decision for its Phase 3 PARAGON trial expected in Q1 2027. NeuroSense Therapeutics is a late-stage clinical biotechnology company developing disease-modifying treatments for neurodegenerative diseases.
NeuroSense Therapeutics Ltd. announced a reverse stock split of its ordinary shares at a ratio of 1-for-20, consolidating every twenty existing shares into one new share. The effective date for trading on the Nasdaq Capital Market is September 14, 2026. This action reduces the issued and outstanding share count from approximately 37.9 million to roughly 1.9 million, with fractional shares rounded up to the nearest whole share rather than paid in cash. Outstanding warrants and options will receive proportionate adjustments to their exercise prices and share counts. The company operates in the biotechnology industry, focusing on developing therapeutic treatments for neurological disorders.
On August 26, 2026, shareholders of NeuroSense Therapeutics Ltd. approved a board authorization to effect one or more reverse share splits at an aggregate ratio ranging from 1-for-4 to 1-for-40. The exact ratio and effective date will be determined by the Board within 12 months. No amendment to the Articles of Association is required for this action. This company operates in the biotechnology industry, focusing on drug discovery.
CEO Alon Ben-Noon announced that NeuroSense Therapeutics is preparing to initiate its pivotal Phase 3 PARAGON study for PrimeC in ALS, which will enroll approximately 300 participants. Securing financing has taken longer than anticipated; however, the CEO and CFO each invested $200,000 in April 2026 alongside a significant existing investor. The company is pursuing strategic partnerships and non-dilutive funding while preparing a New Drug Submission to Health Canada for December 2026 based on Phase 2b data. To address Nasdaq listing deficiencies regarding the minimum bid price, an upcoming shareholder meeting will include a proposal authorizing the Board to effect a reverse share split within a range of 1:4 to 1:40 if necessary. NeuroSense Therapeutics is a late-stage clinical biotechnology company developing disease-modifying treatments for neurodegenerative diseases.